Association of Isocitrate Dehydrogenase (IDH) Status With Edema to Tumor Ratio and Its Correlation With Immune Infiltration in Glioblastoma.
Biomarkers, Tumor
/ genetics
Brain Edema
/ diagnostic imaging
Brain Neoplasms
/ diagnostic imaging
Female
Glioblastoma
/ diagnostic imaging
Humans
Isocitrate Dehydrogenase
/ genetics
Lymphocytes, Tumor-Infiltrating
/ immunology
Magnetic Resonance Imaging
Male
Middle Aged
Mutation
Progression-Free Survival
Retrospective Studies
Tumor Burden
Tumor Microenvironment
dexamethasone
glioma microenvironment
immune infiltration
peritumoral edema
peritumoral edema zone
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
09
11
2020
accepted:
09
03
2021
entrez:
19
4
2021
pubmed:
20
4
2021
medline:
16
9
2021
Statut:
epublish
Résumé
The extent of preoperative peritumoral edema in glioblastoma (GBM) has been negatively correlated with patient outcome. As several ongoing studies are investigating T-cell based immunotherapy in GBM, we conducted this study to assess whether peritumoral edema with potentially increased intracranial pressure, disrupted tissue homeostasis and reduced local blood flow has influence on immune infiltration and affects survival. A volumetric analysis of preoperative imaging (gadolinium enhanced T1 weighted MRI sequences for tumor size and T2 weighted sequences for extent of edema (including the infiltrative zone, gliosis etc.) was conducted in 144 patients using the Brainlab® software. Immunohistochemical staining was analyzed for lymphocytic- (CD 3+) and myelocytic (CD15+) tumor infiltration. A retrospective analysis of patient-, surgical-, and molecular characteristics was performed using medical records. The edema to tumor ratio was neither associated with progression-free nor overall survival (p=0.90, p=0.74). However, GBM patients displaying IDH-1 wildtype had significantly higher edema to tumor ratio than patients displaying an IDH-1 mutation (p=0.01). Immunohistopathological analysis did not show significant differences in lymphocytic or myelocytic tumor infiltration (p=0.78, p=0.74) between these groups. In our cohort, edema to tumor ratio had no significant correlation with immune infiltration and outcome. However, patients with an IDH-1wildtype GBM had a significantly higher edema to tumor ratio compared to their IDH-1 mutated peer group. Further studies are necessary to elucidate the underlying mechanisms.
Identifiants
pubmed: 33868245
doi: 10.3389/fimmu.2021.627650
pmc: PMC8044904
doi:
Substances chimiques
Biomarkers, Tumor
0
Isocitrate Dehydrogenase
EC 1.1.1.41
IDH1 protein, human
EC 1.1.1.42.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
627650Informations de copyright
Copyright © 2021 Dubinski, Won, Rauch, Behmanesh, Ngassam, Baumgarten, Senft, Harter, Bernstock, Freiman, Seifert and Gessler.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
CNS Drugs. 2018 Dec;32(12):1091-1101
pubmed: 30387077
World J Surg Oncol. 2015 Mar 11;13:97
pubmed: 25886608
Brain. 2016 May;139(Pt 5):1458-71
pubmed: 27020328
J Neurooncol. 1996 Jan;27(1):65-73
pubmed: 8699228
Eur J Neurol. 2009 Jul;16(7):874-8
pubmed: 19473360
EMBO Rep. 2011 May;12(5):463-9
pubmed: 21460794
Ther Adv Neurol Disord. 2019 May 14;12:1756286419844664
pubmed: 31205490
Eur Radiol. 2003 Apr;13(4):758-62
pubmed: 12664114
Oncotarget. 2015 May 20;6(14):12094-109
pubmed: 25940437
Cancer Cell. 2011 Jan 18;19(1):17-30
pubmed: 21251613
Front Aging Neurosci. 2015 Oct 31;7:196
pubmed: 26582988
Expert Rev Clin Pharmacol. 2011 Mar;4(2):233-42
pubmed: 21666852
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
J Neurooncol. 2018 May;137(3):503-510
pubmed: 29349612
Curr Oncol. 2014 Jun;21(3):e493-503
pubmed: 24940109
Oncotarget. 2015 Oct 6;6(30):30232-8
pubmed: 26338964
Front Immunol. 2018 May 08;9:1004
pubmed: 29867979
J Neurosurg. 2001 Aug;95(2):190-8
pubmed: 11780887
Neurosurg Focus. 2007 May 15;22(5):E8
pubmed: 17613239
Semin Oncol. 2003 Dec;30(6 Suppl 19):10-4
pubmed: 14765378
Curr Neurol Neurosci Rep. 2013 May;13(5):345
pubmed: 23532369
J Neuropathol Exp Neurol. 2018 Oct 1;77(10):877-882
pubmed: 30060228
Carcinogenesis. 2019 Nov 25;40(11):1299-1307
pubmed: 31504231
Oncoimmunology. 2015 Jun 9;5(1):e1057388
pubmed: 26942067
Sci Transl Med. 2017 Feb 1;9(375):
pubmed: 28148839
Oncotarget. 2018 Feb 20;9(23):16462-16476
pubmed: 29662659
Neurosurg Focus. 2013 Feb;34(2):E2
pubmed: 23373447
Front Immunol. 2019 Jan 22;9:3062
pubmed: 30740109
Neuro Oncol. 2018 Oct 9;20(11):1429-1438
pubmed: 29509936
Neurosurg Rev. 2017 Oct;40(4):621-631
pubmed: 28204997
J Cereb Blood Flow Metab. 2019 Aug;39(8):1460-1468
pubmed: 31238763